Patents by Inventor Evgeny A. Nudler

Evgeny A. Nudler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200149102
    Abstract: A method for detecting rare genomic variants in a population of cells is disclosed. The method can detect de novo mutations in bacteria and analyze the impact of various physiological conditions on mutation rate, even though such effects would be too subtle to detect using other methods. The method can be used for detection of low-frequency subpopulations in the microbiome or in cancer.
    Type: Application
    Filed: November 18, 2019
    Publication date: May 14, 2020
    Inventors: Justin JEE, Bhubaneswar Mishra, Evgeny Nudler
  • Patent number: 10513732
    Abstract: A method for detecting rare genomic variants in a population of cells is disclosed. The method can detect de novo mutations in bacteria and analyze the impact of various physiological conditions on mutation rate, even though such effects would be too subtle to detect using other methods. The method can be used for detection of low-frequency subpopulations in the microbiome or in cancer.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: December 24, 2019
    Assignee: New York University
    Inventors: Justin Lee, Bhubaneswar Mishra, Evgeny Nudler
  • Patent number: 10059944
    Abstract: The invention provides siRNA molecules, combinations of such siRNA molecules, and locked nucleic acid (LNA) antisense oligonucleotides, which target Heat Shock RNA (HSR1) and effectively inhibit stress response in a cell, as well as the use of such siRNA molecules and LNA antisense oligonucleotides for inhibiting inflammatory reactions, inhibiting HIV transcription, and treatment of various diseases, including autoimmune diseases and cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 28, 2018
    Assignee: New York University
    Inventors: Evgeny A. Nudler, Bibhusita Pani
  • Publication number: 20170016062
    Abstract: A method for detecting rare genomic variants in a population of cells is disclosed. The method can detect de novo mutations in bacteria and analyze the impact of various physiological conditions on mutation rate, even though such effects would be too subtle to detect using other methods. The method can be used for detection of low-frequency subpopulations in the microbiome or in cancer.
    Type: Application
    Filed: July 11, 2016
    Publication date: January 19, 2017
    Inventors: Justin JEE, Bhubaneswar Mishra, Evgeny Nudler
  • Publication number: 20160122757
    Abstract: The invention provides siRNA molecules and LNA antisense oligonucleotides, which target Heat Shock RNA (HSR1) and effectively inhibit stress response in a cell, and their use for treatment of various diseases.
    Type: Application
    Filed: March 14, 2014
    Publication date: May 5, 2016
    Applicant: New York University
    Inventors: Evgeny A. NUDLER, Bibhusita PANI
  • Patent number: 8889850
    Abstract: The present invention is directed to molecules that inhibit expression or a function of a eukaryotic Heat Shock RNA (HSR1) and their use for inhibiting a stress response or stress tolerance in a cell.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: November 18, 2014
    Assignee: New York University
    Inventors: Evgeny A. Nudler, Ilya Shamovsky
  • Patent number: 8889634
    Abstract: This invention discloses isolated short peptides comprising the amino acid sequence Cys-Glu-Phe-His (CEFH; SEQ ID NOS: 1 and 15) and analogs thereof as well as compositions comprising CEFH peptides and analogs thereof. The CEFH peptides disclosed herein are effective in mediating the denitration of 3-nitrotyrosines (3-NT) in cellular proteins thereby preventing tissue damage associated with excess nitric oxide (NO) and its reactive species. The CEFH peptides disclosed herein are useful in the treatment of ischemia/reperfusion (I/R) injury and other disorders.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: November 18, 2014
    Assignee: New York University
    Inventors: Evgeny A. Nudler, Ruslan R. Rafikov
  • Patent number: 8709743
    Abstract: The invention relates in part to compounds that act as highly nitric oxide (NO)-specific turn-on fluorescent probes. The present invention also relates to the use of these fluorescein-based sensors to screen selectively for inhibitors of bacterial nitric oxide synthase (bNOS). Compounds of the present invention readily detect nitric oxide produced in vivo. Therefore they can be used in an assay that measures NO production by bNOS. Using a sensor of the invention one can screen libraries of small molecules for inhibitors of bNOS.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: April 29, 2014
    Assignee: Massachusetts Institute of Technology
    Inventors: Stephen J. Lippard, Lindsey E. McQuade, Evgeny A. Nudler
  • Publication number: 20140066362
    Abstract: The invention provides materials and methods for treating infections by reducing endogenous microbial H2S levels.
    Type: Application
    Filed: February 1, 2012
    Publication date: March 6, 2014
    Applicant: NEW YORK UNIVERSITY
    Inventors: Evgeny A. Nudler, Konstantin Shatalin
  • Patent number: 8389482
    Abstract: This invention discloses isolated short peptides comprising the amino acid sequence Cys-Glu-Phe-His (CEFH; SEQ ID NOS: 1 and 15) and analogs thereof as well as compositions comprising CEFH peptides and analogs thereof. The CEFH peptides disclosed herein are effective in mediating the denitration of 3-nitrotyrosines (3-NT) in cellular proteins thereby preventing tissue damage associated with excess nitric oxide (NO) and its reactive species. The CEFH peptides disclosed herein are useful in the treatment of ischemia/reperfusion (I/R) injury of various tissues (e.g., I/R injury of heart muscle associated with heart attack or cardiac surgery, I/R injury of brain tissue associated with stroke, I/R injury of liver tissue, skeletal muscles, etc.), septic shock, anaphylactic shock, neurodegenerative diseases (e.g.
    Type: Grant
    Filed: May 3, 2007
    Date of Patent: March 5, 2013
    Assignee: New York University
    Inventors: Evgeny A. Nudler, Ruslan R. Rafikov
  • Publication number: 20120172292
    Abstract: This invention discloses a method for enhancing the efficacy of antimicrobial, anti-protozoa and anti-cancer treatments by co-administering an inhibitor of endogenous NO production and/or NO scavenger.
    Type: Application
    Filed: September 10, 2010
    Publication date: July 5, 2012
    Applicant: NEW YORK UNIVERSITY
    Inventors: Evgeny A. Nudler, Ivan Gusarov
  • Publication number: 20120142100
    Abstract: The present invention provides a novel RNA, designated herein as the “HSR1” (Heat Shock RNA), and its use together with translation elongation factor eEF1A in activation of heat shock transcription factor HSF. The invention further provides the use of HSR1 for generation of novel therapeutics for the treatment of various diseases in animals and for generation of stress-resistant plants.
    Type: Application
    Filed: October 13, 2011
    Publication date: June 7, 2012
    Applicant: NEW YORK UNIVERSITY
    Inventors: Evgeny A. Nudler, Ilya Shamovsky
  • Patent number: 8067558
    Abstract: The present invention provides a novel RNA, designated herein as the “HSR1” (Heat Shock RNA), constitutively active HSR1 fragments, and the use of HSR1 and constitutively active HSR1 fragments for generation of novel therapeutics for the treatment of various diseases in animals and for generation of stress-resistant plants.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: November 29, 2011
    Assignee: New York University
    Inventors: Evgeny A. Nudler, Ilya Shamovsky
  • Patent number: 8044101
    Abstract: Biomacromolecules such as proteins are inactivated by hydrophobic ANSA derivatives of the formula: wherein R1 and R2 are hydrophobic or affinity groups and R3 is selected from the group consisting of aminoacyl groups and peptidyl groups upon nitrosation. ANSA derivatives can be designed to selectively kill tumor cells and various pathogens, including bacteria, viruses, and fungi.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: October 25, 2011
    Assignee: New York University
    Inventors: Evgeny Nudler, Audrei Nedospasov
  • Publication number: 20110201042
    Abstract: The invention relates in part to compounds that act as highly nitric oxide (NO)-specific turn-on fluorescent probes. The present invention also relates to the use of these fluorescein-based sensors to screen selectively for inhibitors of bacterial nitric oxide synthase (bNOS). Compounds of the present invention readily detect nitric oxide produced in vivo. Therefore they can be used in an assay that measures NO production by bNOS. Using a sensor of the invention one can screen libraries of small molecules for inhibitors of bNOS.
    Type: Application
    Filed: December 17, 2008
    Publication date: August 18, 2011
    Applicant: Massachusetts Institute of Technology
    Inventors: Stephen J. Lippard, Lindsey E. McQuade, Evgeny A. Nudler
  • Patent number: 7919603
    Abstract: The present invention provides a novel RNA, designated herein as the “HSR1” (Heat Shock RNA), and its use together with translation elongation factor eEF1A in activation of heat shock transcription factor HSF. The invention further provides the use of HSR1 for generation of novel therapeutics for the treatment of cancer, inflammation, ischemia, neurodegeneration, age-related diseases, HIV infection, deafness, and related disorders.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: April 5, 2011
    Assignee: New York University
    Inventors: Evgeny A. Nudler, Ilya Shamovsky
  • Patent number: 7767232
    Abstract: Perfluorocarbons are used to control nitric oxide metabolism, either to inhibit nitric oxide activity or to potentiate the effects of nitric oxide. Perfluorocarbons can be used, for example, to treat hypotension and vasoplegia in septic shock, to protect against myocardial ischemia-reperfusion injury, to treat hypertension, and to provide antiplatelet effects.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: August 3, 2010
    Assignee: New York University
    Inventors: Evgeny Nudler, Ruslan Rafikova, Olga Rafikova
  • Publication number: 20090186829
    Abstract: Biomacromolecules such as proteins are inactivated by hydrophobic ANSA derivatives of the formula: wherein R1 and R2 are hydrophobic or affinity groups and R3 is selected from the group consisting of aminoacyl groups and peptidyl groups upon nitrosation. ANSA derivatives can be designed to selectively kill tumor cells and various pathogens, including bacteria, viruses, and fungi.
    Type: Application
    Filed: March 26, 2009
    Publication date: July 23, 2009
    Applicant: New York University
    Inventors: Evgeny NUDLER, Audrei NEDOSPASOV
  • Publication number: 20090188009
    Abstract: The present invention provides a novel RNA, designated herein as the “HSR1” (Heat Shock RNA), and its use together with translation elongation factor eEF1A in activation of heat shock transcription factor HSF. The invention further provides the use of HSR1 for generation of novel therapeutics for the treatment of various diseases in animals and for generation of stress-resistant plants.
    Type: Application
    Filed: October 31, 2008
    Publication date: July 23, 2009
    Applicant: New York University
    Inventors: Evgeny A. Nudler, Ilya Shamovsky
  • Patent number: 7511076
    Abstract: Biomacromolecules such as proteins are inactivated by hydrophobic ANSA derivatives of the formula: wherein R1 and R2 are hydrophobic or affinity groups and R3 is selected from the group consisting of aminoacyl groups and peptidyl groups upon nitrosation. ANSA derivatives can be designed to selectively kill tumor cells and various pathogens, including bacteria, viruses, and fungi.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: March 31, 2009
    Assignee: New York University
    Inventors: Evgeny Nudler, Andrei Nedospasov